Understanding how specific proteins interact to prevent lung cancer growth
Official title: Pdcd4-Rictor Interaction in Suppression of Lung Tumorigenesis
Funded at University of Kentucky · NIH-10932407 · Data updated 2026-11-12
This study is looking at how two proteins work together to help stop lung tumors from growing, with the goal of finding new treatments that could make a real difference for people with lung cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project start | September 20, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $482,326 |
| NIH project number | 5R01CA279455-02 |
| Project ID | NIH-10932407 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC), particularly those with Rictor gene amplification.
✕Less likely to help
Patients with lung cancer types not related to Rictor amplification or those with advanced-stage disease may not benefit from this research.
What this research studies
This research investigates the interaction between two proteins, Pdcd4 and Rictor, to understand how they can suppress the growth of lung tumors. By studying the mechanisms that lead to lung cancer, particularly focusing on the mTORC2 pathway, the research aims to identify new therapeutic approaches that could improve treatment outcomes for patients. The team will use various biological assays and models to explore how inhibiting this interaction can affect cancer cell proliferation and survival. This could lead to the development of targeted therapies that are more effective against lung cancer.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve survival rates for lung cancer patients.
How similar studies have gone: Other research has shown promising results in targeting the mTOR pathway for cancer treatment, suggesting that this approach may be effective.
Where this research is happening
-
University of Kentucky
Lexington, United States Active
Researchers
- Principal investigator: Yang, Hsin-Sheng — University of Kentucky
- Study coordinator: Yang, Hsin-Sheng
Related research
Other NIH-funded projects on the same topics.
-
East Palestine health impact study following train derailment
A community-engaged study in East Palestine will follow residents to understand health symptoms, exposure markers, and air quality after a major train derailment.
-
Grade C Periodontitis in Young People: Genetic Clues to a Severe, Early Condition
A research team is studying why some young people develop a severe form of gum disease called Grade C periodontitis and how genetics and bacteria like Aa may contribute.
-
Regulation of exon junction complex in cancer biology
This grant studies how a key molecular complex that controls RNA processing acts in cancer, with the aim of understanding how it contributes to cancer cell behavior.
-
Alcohol use and suicidal thoughts: how decision-making affects risk
This project looks at how acute alcohol use and people’s decision-making patterns relate to suicidal thoughts and behaviors in adults.
-
Kentucky workplace health surveillance program improving safety for workers
A national institute-funded program is supporting Kentucky to monitor and improve safety and health at work for better protection of workers.
-
Gabapentin use in older adults and related health outcomes
This project will look at how gabapentin is used by older adults and whether that use is linked to health outcomes using Medicare data.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.